Full-Time

Distribution Enablement Lead / Wealth

Updated on 7/25/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

€85k - €175k/yr

+ Bonus + Incentives

London, UK

Hybrid

In-office 4 days per week with 1 day remote; role can be based in Hong Kong or London; Singapore not listed as base location.

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to Wellington Management

Find people who can refer or advise you

Requirements
  • 5 years of experience in Sales Enablement, COO functions, or Senior Training and Adoption roles within Banking, Finance, or Insurance
  • Proven track record with large-scale change initiatives spanning sales, marketing, and management
  • Experience collaborating with product owners and engineering teams to clarify business objectives and requirements
  • Strong understanding of sales processes, with experience in a client-facing role or direct support of field sales
  • Demonstrated ability to influence key stakeholders and implement strategic plans
  • Experience with sales CRM platforms and sales workflow solutions
  • Bachelor's degree
Responsibilities
  • Partnering with EMEA/APAC Wealth sales leadership development and drive the enablement roadmap
  • Lead change management and adoption strategy for Wealth sales enablement initiatives that will scale globally
  • Build relationships across the front office and become primary enablement resource to the front office, providing enablement support and applying deep sales process expertise
  • Identify change champions and drive adoption across teams and functions; proliferate best practices. Participate in territory business planning, embedding bespoke tactics and execution strategies, serving as a thought partner to sales and an execution conduit
  • Drive and deliver communication, training, and stakeholder engagement plans
  • Develop data-driven executive narratives that articulate digital priorities and enterprise impact
  • Participate in vendor evaluation, selection, and implementation planning
  • Measure success through defined adoption KPIs and associated business impact; provide regular reporting and insights to leadership
Desired Qualifications
  • 8-10+ years of relevant professional experience, including at least 5 years in Sales Enablement, COO functions, or Senior Training and Adoption roles within Banking, Finance, or Insurance
  • Local expertise capturing the regional nuances of asset management distribution
  • Strong understanding of the asset management industry, with familiarity of alternative, fund and ETF investment products and distribution channels
  • Experience designing and implementing programs that enhance sales productivity, effectiveness, and technology adoption
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$63.3B

Headquarters

Boston, Massachusetts

Founded

1933

Get referred to Wellington Management

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $67M lead investment in Climate First Bank positions Wellington ahead of its potential IPO.
  • Dedicated private climate team expands into food, agriculture, and industrial automation sectors.
  • $90K-$180K Associate hire signals strong growth in Wellington's climate venture strategy.

What critics are saying

  • Passive ESG index funds compress fees, eroding AUM revenue by 5-8% annually within 12-18 months.
  • Climate First Bank IPO failure could trigger $200M+ AUM loss and client mandate withdrawals in 6-12 months.
  • EU reclassifies nonconcessionary climate strategies as high-risk, forcing disclosures and client exits in 9-15 months.

What makes Wellington Management unique

  • Wellington leads climate innovation with $385M first fund focused on tech-enabled climate solutions.
  • The firm uses proprietary CERA tool for geospatial analysis of physical climate risks against client assets.
  • Wellington offers differentiated private climate investing targeting adaptation and mitigation across energy and agriculture.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.